CpG adjuvant and application thereof

By designing the CpG sequence and plasmid multi-copy double-stranded CpG sequence based on the GTCGTT and ATCGAT motifs, as a vaccine adjuvant, the shortcomings of existing vaccine adjuvant in the improvement of the immune response of Chicken Newcastle Disease and Avian Influenza H9 subtype virus are solved, and the immune response of existing vaccine adjuvant is achieved. The effect of significantly improving the antibody level of chicken flocks.

CN118910110APending Publication Date: 2024-11-08天津万牧生生物工程有限责任公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410969960.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing vaccine adjuvants have limitations in improving immune response, especially in improving immune responses to Chicken Newcastle Disease and Avian Influenza H9 subtype viruses, and lack safe and efficient immune stimulation methods.

Method used

A series of CpG sequences based on GTCGTT and ATCGAT motifs were designed, and combined with plasmid multi-copy double-stranded CpG sequences were used as adjuvant for chicken vaccines, including SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO. .5 CpG ODN and plasmid sequences were used in the composition of the H9 subtype of chicken inoculation and avian influenza H9 subtype. CpG adjuvant was formed through the NheI cloning site of the pcDNA 3.1(+) plasmid.

Benefits of technology

Through experimental analysis, CpG-ODN such as ODN101, ODN103 and ODN105 was determined as the optimal adjuvant. pcDNA 3.1-CpG1 significantly improved the immune effect of the double-inactivated vaccine of Chicken Newcastle Disease and Avian Influenza H9 subtype, and significantly improved the chicken flock's anti-virus against viruses Level of antibody production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910110A_ABST
    Figure CN118910110A_ABST
Patent Text Reader

Abstract

The invention discloses a CpG adjuvant and application thereof, and belongs to the technical field of biological products. The CpG adjuvant is any one of the following components: (1) any one of CpG ODNs of which the sequences are as shown in SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and (2) any one of CpG ODNs of which the sequences are as shown in SEQ ID NO.3 and SEQ ID NO.5; and (2) a plasmid containing the sequence as shown in SEQ ID NO.9, the plasmid is a pcDNA 3.1 (+) plasmid, and the cloning site of the sequence as shown in SEQ ID NO.9 in the pcDNA 3.1 (+) plasmid is NheI. The invention provides a new direction for improving the effect of the newcastle disease and avian influenza H9 subtype bivalent inactivated vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biological products, and in particular relates to a CpG adjuvant and an application thereof. Background Art

[0002] An adjuvant is an ingredient used in some vaccines that helps to produce a stronger immune response in the body that receives the vaccine. In other words, adjuvants help vaccines work better. Aluminum salts, such as aluminum hydroxide, aluminum phosphate, and potassium aluminum sulfate have been safely used in vaccines for more than 70 years. Aluminum salts were first used in diphtheria and tetanus vaccines in the 1930s, 1940s, and 1950s because it was found that aluminum salts can enhance the body's immune response to these vaccines. In addition to aluminum salt adjuvants, oil emulsion adjuvants, nanoparticle adjuvants, and water adjuvants are constantly being used in vaccines.

[0003] Pathogen-associated molecular patterns are expressed by a variety of infectious microorganisms. For example, lipopolysaccharides and lipoproteins on bacterial cell walls are recognized by TLR4 and TLR2; flagellin is the main component of bacterial flagella and is recognized by TLR5; dsRNA is recognized by TLR3, while ssRNA is detected by TLR7 / 8. Unmethylated CpG motifs present in bacterial and viral DNA can be recognized by TLR9 (referred to as CpGDNA).

[0004] Synthetic oligodeoxynucleotides (ODNs) containing unmethylated CpG motifs trigger cells expressing toll-like receptor 9 (including human plasmacytoid dendritic cells and B cells). The immunostimulatory and species-specific activities of CpG-ODNs depend on their nucleotide sequence characteristics, including CpG hexamer motif type, motif spacing, nucleotide sequence, and length. Toll-like receptor (TLR) 9 is the cellular receptor for mammalian CpG-ODNs, and TLR21 is the cellular receptor for avian CpG-ODNs. Mammalian cells lack TLR21, and avian cells lack TLR9. CpG-ODNs stimulate the body's innate immune response characterized by the production of Th1 and proinflammatory cytokines. When used as a vaccine adjuvant, CpG-ODNs can improve the function of professional antigen-presenting cells and promote the generation of humoral and cellular vaccine-specific immune responses. The adjuvant properties of CpGODNs can be effective when administered systemically or mucosally and persist in immunocompromised hosts. Clinical studies have shown that CpGODNs can play a good role in vaccines for infectious diseases and cancer. In addition, CpGODNs has good safety.

[0005] According to earlier reports, GTCGTT is the best stimulation sequence for humans, and GACGTT is the best stimulation sequence for mice, but current research results have found that GTCGTT also has a very good activation effect on chickens, pigs, sheep and cattle. In addition, it has been reported that ATCGAT has a significant activation effect on chicken peripheral blood mononuclear cells. In addition to the differences in sequence motifs, the types of CpG-ODN can be divided into type A, type B and type C, among which type C has the advantages of both type A and type B, and has an obvious feature in configuration - palindrome structure. Summary of the invention

[0006] The present invention designs a series of CpG sequences based on the GTCGTT and ATCGAT motifs and the C-type palindromic structure to study their application in vaccine adjuvants. In addition, the present invention also verifies the effect of multi-copy double-stranded CpG sequences based on plasmids.

[0007] The present invention provides a CpG adjuvant, wherein the CpG adjuvant is any one of the following:

[0008] (1) any one of the CpG ODNs whose sequences are shown in SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5;

[0009] (2) A plasmid containing the sequence shown in SEQ ID NO.9.

[0010] Furthermore, the plasmid in (2) is a pcDNA 3.1(+) plasmid.

[0011] Furthermore, the cloning site of the sequence shown in SEQ ID NO.9 in (2) in the pcDNA 3.1(+) plasmid is NheI.

[0012] The present invention also provides a chicken vaccine composition, which contains an effective amount of the CpG adjuvant.

[0013] Furthermore, the vaccine in the chicken vaccine composition is a combined inactivated vaccine of Newcastle disease and avian influenza H9 subtype.

[0014] Furthermore, the chicken vaccine composition is calculated based on the total volume, and the concentration of the CpG adjuvant is 0.5-4 μg

[0015] / 0.3ml.

[0016] Furthermore, the chicken vaccine composition has a CpG adjuvant concentration of 1 μg / 0.3 ml calculated on a total volume basis.

[0017] Furthermore, the chicken vaccine composition has a CpG adjuvant concentration of 3 μg / 0.3 ml calculated on a total volume basis.

[0018] The present invention also provides the use of the CpG adjuvant in preparing a chicken vaccine composition.

[0019] Furthermore, the vaccine in the chicken vaccine composition is a combined inactivated vaccine of Newcastle disease and avian influenza H9 subtype.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] The present invention determines at least three groups of CpG-ODN effective immune adjuvants through experimental analysis, among which ODN101, ODN103 and ODN105 are the best. For the biosynthetic CpG combined double-stranded sequence, pcDNA 3.1-CpG1 is the best. The present invention provides a new direction for improving the effect of Newcastle disease and avian influenza H9 subtype two-inactivated vaccine. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 This is the mass spectrometry detection result of ODN101 in Example 1.

[0023] Figure 2 This is the mass spectrometry detection result of ODN102 in Example 1.

[0024] Figure 3 This is the mass spectrometry detection result of ODN103 in Example 1.

[0025] Figure 4 This is the mass spectrometry detection result of ODN104 in Example 1.

[0026] Figure 5 This is the mass spectrometry detection result of ODN105 in Example 1.

[0027] Figure 6 This is the mass spectrometry detection result of ODN106 in Example 1.

[0028] Figure 7 This is the mass spectrometry detection result of ODN107 in Example 1.

[0029] Figure 8 This is the mass spectrometry detection result of ODN108 in Example 1.

[0030] Fig. 9 The results of nucleic acid electrophoresis of ODN101-ODN108 in Example 1, from left to right are ODN101, ODN102, ODN103, ODN104, Maker, ODN105, ODN106, ODN107, and ODN108.

[0031] Fig.10 This is the sequencing result of pcDNA 3.1-CpG1 in Example 1.

[0032] Fig.11 This is the electrophoresis result of pcDNA 3.1-CpG1 in Example 1.

[0033] Fig.12 This is the sequencing result of pcDNA 3.1-CpG2 in Example 1.

[0034] Fig.13 The electrophoresis results of pcDNA 3.1-CpG2 in Example 1 are, from left to right, pcDNA 3.1-CpG2 without enzyme digestion, pcDNA 3.1-CpG2 digested with ScaI and BamHI, and ladder.

[0035] Fig.14 This is the peripheral blood H9 antibody level of broiler chickens immunized with the new bivalent vaccine in Example 1 (CpG-ODN adjuvant).

[0036] Fig.15 This is the peripheral blood ND antibody level of broiler chickens immunized with the new bivalent vaccine in Example 1 (CpG-ODN adjuvant).

[0037] Fig.16 This is the peripheral blood H9 antibody level of broiler chickens immunized with the new bivalent vaccine in Example 1 (pcDNA 3.1-CpG adjuvant).

[0038] Fig.17 This is the ND antibody level in the peripheral blood of broilers immunized with the new bivalent vaccine in Example 1 (pcDNA 3.1-CpG adjuvant). DETAILED DESCRIPTION

[0039] The oil phase in the following examples all refers to mineral oil containing 6% Span 80, and ND+H9 is an inactivated antigen.

[0040] Example 1

[0041] 1.1 Ingredient Type

[0042] Chemical synthesis of CpG-ODN;

[0043] CpG combination double-stranded sequences in plasmid vectors.

[0044] 1.2 Ratio of each ingredient

[0045] Add 0.1-10ug per vaccine.

[0046] 1.3 CpG-ODN design

[0047] Table 1 List of CpG-ODN

[0048]

[0049] Asterisks represent thio modification.

[0050] 1.4pcDNA 3.1-CpG combination design

[0051] >pcDNA 3.1-CpG1 (SEQ ID NO.9)

[0052] GCTAGCGGTGCATCGATTTGCTTATCGATTTGCTTTTGCTTATCGATTCGATCGATATCG

[0053] ATTCGATCGATATCGATTCGTTGCTTTCGTTGCTTTCGTTGCTTATCGATTCGATCGATA

[0054] TCGATTCGATCGATATCGATTCGATCGATTCGATCGATATCGATTCGATCGATATCGATGCAGGGGGGGCTAGC.

[0055] Cloning site: NheI

[0056] >pcDNA 3.1-CpG2 (SEQ ID NO.10)

[0057] GCTAGCTCGTCGATCGATATCGATTTGATCGGTGCATCGATGCAGGGGGGTCGTCGATC

[0058] GATATCGATTTGATCGGTGCATCGATGCAGGGGGGTCGTCGATCGATATCGATTTGATC

[0059] GGTGCATCGATGCAGGGGGGTCGTCGATCGATATCGATTTGATCGGTGCATCGATGCAGGGGGGTCGTCGATCGATATCGATTTGATCGGTGCATCGATGCAGGGGGGGCTAGC.

[0060] Cloning site: NheI

[0061] 1.5 Sample preparation

[0062] 1.5.1 CpG-ODN

[0063] The CpG-ODN samples were synthesized by the solid phase method at Suzhou Jinweizhi Biotechnology Co., Ltd.

[0064] 1.5.2pcDNA 3.1-CpG

[0065] The double-stranded CpG gene was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd. through the solid phase method, then constructed into the pcDNA 3.1(+) vector and transformed into DH5ɑ competent cells.

[0066] (1) Buffer configuration:

[0067] STET buffer: 50 mM glucose; Tris-HCl 25 mM pH 8.0; EDTA 10 mM; Triton X-100 20 g / L.

[0068] Lysis buffer: NaOH 0.2M; SDS 1%.

[0069] Neutralization buffer: Sodium acetate 3.0 M pH 4.8-5.2.

[0070] (2) Operating procedures

[0071] Redissolution: Take 25g of bacterial sludge and dissolve it fully with 200ml STET buffer (concentration is about OD600=100), and be careful not to have bacterial lumps;

[0072] Lysis: Add 400 ml of 0.2 M sodium hydroxide solution to the dissolved bacterial solution, mix gently, and let stand at room temperature for 2 minutes;

[0073] Neutralization: Add 300 ml 3.0 M sodium acetate, pH 4.8-5.2, mix gently, and incubate at 68°C with stirring for 10 min.

[0074] Collect the supernatant: Centrifuge at 6000 rpm for 20 min and take the supernatant for later use;

[0075] Alcohol precipitation: add the supernatant to 0.6 times the volume of isopropanol, mix well, and incubate at room temperature for 30 minutes;

[0076] Washing: centrifuge at 6000 rpm for 20 min, discard the supernatant, and wash twice with appropriate volume of ethanol;

[0077] Redissolve: dissolve the precipitate with 20 ml of water;

[0078] Molecular sieve purification: dilute the solution to 300ug / ml and purify by molecular sieve chromatography;

[0079] Ion exchange purification: The target product is purified by anion chromatography on the collected fractions.

[0080] (3) Concentration and purity determination

[0081] Take an appropriate amount of this product and dilute it with purified water, shake well. Determination: Use purified water as a blank control, use a UV spectrophotometer to measure the absorbance values ​​A260 and A280 at 260nm and 280nm respectively, and calculate A260 / A280. The ratio of A260 / A280 is 1.6 to 2.0.

[0082] Calculate the concentration and purity of the sample to be tested:

[0083] Concentration calculation formula:

[0084]

[0085] Where: the product conversion factor is 50.

[0086] Purity calculation formula:

[0087] Purity = OD 260 / OD 280

[0088] 1.6 Sample testing

[0089] 1.6.1 CpG-ODN samples

[0090] The mass spectrometry analysis method of primers is a technology used to detect the molecular weight of primers. It uses electric and magnetic fields to separate the moving ions according to their mass-to-charge ratio and then detect them, thereby effectively identifying the accuracy of the primer synthesis sequence. This method can be used to detect the purity and molecular weight of the full-length sequence of primers, clarify the type of impurities, and semi-quantify impurities (impurity ratio). It is suitable for DNA primers or chemically synthesized RNA (within 200nt).

[0091] Sample preparation: Dissolve the primer sample to be tested in an appropriate solvent, usually water or buffer, to achieve a suitable concentration.

[0092] Instrument preparation: Turn on the mass spectrometer and preheat and calibrate according to the instrument operating manual. Select a mass spectrometry mode suitable for analyzing primers, such as electrospray ionization (ESI) or matrix-assisted laser desorption ionization (MALDI).

[0093] Injection: Inject the sample into the mass spectrometer using an autosampler or manual injection.

[0094] Data acquisition: Set appropriate mass spectrometry parameters, such as ion source voltage, mass range, and scan speed. Start the data acquisition program to obtain the mass spectrum of the primer.

[0095] Data analysis: Process and analyze the collected mass spectrometry data. Determine the molecular weight of the primer and compare it with the theoretical molecular weight to determine whether the primer synthesis is accurate. Check for the presence of impurity peaks and evaluate their relative content.

[0096] Result report: Organize the analysis results and generate a report, including information such as the molecular weight of the primers, purity assessment, possible impurities, etc.

[0097] Primer electrophoresis is a commonly used analytical method, which is mainly used to evaluate the quality and purity of primers. The basic steps are as follows:

[0098] Gel preparation: Agarose gel is usually used and the appropriate concentration should be selected according to needs.

[0099] Sample preparation: Mix the primer sample to be tested with loading buffer.

[0100] Loading: Carefully add the mixed sample to the loading wells of the gel.

[0101] Electrophoresis: Turn on the power supply and make the sample move toward the positive electrode under the action of the electric field.

[0102] Detection: After electrophoresis, observe the electrophoresis bands under fluorescence.

[0103] During electrophoresis, primers migrate in the gel according to their molecular weight. Primers with smaller molecular weights migrate faster, while primers with larger molecular weights migrate slower. By comparing with standards of known molecular weight, it is possible to determine whether the molecular weight of the primers meets expectations, and whether there are degradation products, impurities, etc. In addition, the brightness of the bands can be used to make a preliminary estimate of the concentration of the primers. Clear, single bands usually indicate that the primers are of high purity; while multiple, fuzzy bands may indicate quality issues with the primers.

[0104] 1.6.2pcDNA 3.1-CpG

[0105] (1) Sequencing analysis

[0106] Sanger sequencing is a classic DNA sequencing method. The following are its specific steps:

[0107] Template preparation: Extract the DNA fragment to be sequenced, which can be a specific fragment obtained by PCR amplification, or a genomic DNA fragment extracted from cells or tissues.

[0108] Primer design: Design appropriate primers for the target DNA fragment. The length of the primer is usually 20 nucleotides.

[0109] Sequencing reaction: DNA template, primers, DNA polymerase, four deoxynucleotides (dNTPs) and a small amount of dideoxynucleotides (ddNTPs) are added to the reaction system. ddNTPs lack 3'-OH groups, and once incorporated into the newly synthesized DNA chain, the extension of the chain will be terminated.

[0110] Denaturation and separation: After the reaction is completed, the product is denatured to convert the double-stranded DNA into a single-stranded DNA. The product is then separated by polyacrylamide gel electrophoresis or capillary electrophoresis.

[0111] Detection and analysis: During electrophoresis, DNA fragments of different lengths will migrate to different locations in the gel. The fluorescent markers or radioactive markers at the ends of the DNA fragments are detected by fluorescence detection autoradiography. The DNA sequence is read based on the locations of DNA fragments of different lengths and the marker signals.

[0112] (2) Electrophoresis detection

[0113] This method is a commonly used analytical method, mainly used to evaluate the quality and purity of primers. Its basic steps are as follows:

[0114] Gel preparation: Agarose gel is usually used and the appropriate concentration should be selected according to needs.

[0115] Sample preparation: Mix the primer sample to be tested with loading buffer.

[0116] Loading: Carefully add the mixed sample to the loading wells of the gel.

[0117] Electrophoresis: Turn on the power supply and make the sample move toward the positive electrode under the action of the electric field.

[0118] Detection: After electrophoresis, observe the electrophoresis bands under fluorescence.

[0119] During electrophoresis, primers migrate in the gel according to their molecular weight. Primers with smaller molecular weights migrate faster, while primers with larger molecular weights migrate slower. By comparing with standards of known molecular weight, it is possible to determine whether the molecular weight of the primers meets expectations, and whether there are degradation products, impurities, etc. In addition, the brightness of the bands can be used to make a preliminary estimate of the concentration of the primers. Clear, single bands usually indicate that the primers are of high purity; while multiple, fuzzy bands may indicate quality issues with the primers.

[0120] 1.7 Animal Immunization Test

[0121] 1.7.1 CpG-ODN samples

[0122] Vaccine preparation: First, prepare the CpG-ODN sample at a concentration of 300ug / ml. Add 3ug of vaccine to the antigen for each dose and mix well. Then slowly pour it into the oil phase (mineral oil containing 6% Span 80), with a water-oil ratio of 1:2. Use Fluke F6 / 10, G6 blade, 6000rpm, emulsify for 2min, and the monitoring temperature should not rise to the point where it feels warm. No CpG-ODN sample is added to the vaccine control group, and no antigen is added to the blank control group. Place in a 2-8℃ refrigerator for observation for 15 days, and the emulsion should not break.

[0123] The experiment was divided into 10 groups, with 600 7-day-old white-feathered broilers, and the immunization dosage was 0.3 ml / bird, and the immunization site was subcutaneous in the back of the neck. The antibody levels were tested before immunization, 14 days, 21 days, 28 days and 35 days after immunization. 20 birds were randomly selected from each group for blood collection, serum separation, and serum antibody testing.

[0124] Table 2 CpG-ODN vaccine preparation ratio

[0125]

[0126] 1.7.2pcDNA 3.1-CpG

[0127] Vaccine preparation: First, prepare the pcDNA 3.1-CpG sample at a concentration of 300ug / ml. Add 1ug of vaccine to the antigen for each dose and mix evenly. Then slowly pour it into the oil phase with a water-oil ratio of 1:2. Use Fluke F6 / 10, G6 blade, 6000rpm, emulsify for 2min, and the monitoring temperature should not rise to the point where it feels warm. No pcDNA 3.1-CpG sample is added to the vaccine control group, and no antigen is added to the blank control group. Place in a 2-8℃ refrigerator for observation for 15 days, and the emulsion should not break.

[0128] The experiment was divided into 4 groups, with 240 7-day-old white-feathered broilers. The immunization dosage was 0.3 ml / bird, and the immunization site was subcutaneous on the back of the neck. The antibody levels were tested before immunization, 14 days, 21 days, 28 days and 35 days after immunization. 20 birds were randomly selected from each group for blood collection, serum separation and serum antibody detection.

[0129] Table 3 pcDNA3.1-CpG vaccine preparation ratio

[0130]

[0131] 1.8 Test results and discussion

[0132] 1.8.1 Sample testing

[0133] (1) CpG-ODN samples

[0134] According to the mass spectrometry results, ODN101, ODN102, ODN103, ODN104, ODN105, ODN106, ODN107, and ODN108 meet the design expectations ( Figure 1-Figure 8 ), and electrophoresis also confirmed the results ( Fig. 9 ).

[0135] (2) pcDNA 3.1-CpG

[0136] According to the sequencing results ( Fig.10 and Fig.12 ), the sequencing results of CpG1 and CpG2 are completely consistent with the designed sequences. According to the electrophoresis results ( Fig.11 and Fig.13 ), CpG1 and CpG2 sequences have been inserted into the pcDNA 3.1 vector, namely pcDNA 3.1-CpG1 and pcDNA 3.1-CpG2.

[0137] 1.8.2 Animal Immunization Test

[0138] (1) CpG-ODN samples

[0139] Peripheral blood was collected from 20 broilers randomly selected from each group of immunized white-feathered broilers at 14, 21, 28 and 35 days after immunization. Peripheral blood was collected from 20 broilers randomly selected from the flock before immunization. Serum was separated and antibody levels were tested. The results showed that the blank control serum antibody gradually decreased and was almost zero at 28 and 35 days, indicating that the flock was not infected with wild virus and the experiment was established. Fig.14 ), compared with the antigen control group, the antibody levels were relatively low on the 14th day, and the adjuvant did not work; on the 21st day, the antibodies of the ODN105 group and ODN107 group were higher than 2 titers, the ODN103 group was higher than 1 titer, the ODN102 group and ODN108 group were slightly improved, and the ODN104 group and ODN106 were basically the same; on the 28th day, the ODN101 group, ODN103 group, ODN105 group and ODN107 were all higher than 2 titers, the ODN102 group was higher than 1 titer, the ODN108 group was slightly improved, and the ODN104 and ODN106 were lower than the antigen control group; on the 35th day, the ODN103 and ODN105 groups were higher than 2 titers, the ODN101 group, ODN102 group and ODN107 group were higher than 1 titer, the ODN106 and ODN108 groups were basically the same, and the ODN104 group was lower than the antigen control group.

[0140] Peripheral blood was collected from 20 broilers randomly selected from each group of immunized white-feathered broilers at 14, 21, 28 and 35 days after immunization. Peripheral blood was collected from 20 broilers randomly selected from each group before immunization. Serum was separated and antibody levels were tested. The results show that ( Fig.15), the blank control serum antibody gradually decreased and was almost zero at 28 days and 35 days, indicating that the chickens were not infected with wild toxins and the experiment was established. Regarding ND antibodies, compared with the antigen control, at 14 days, the titers of ODN101, ODN102, ODN103 and ODN105 groups increased by about 1, the ODN107 group was basically the same, and the ODN104, ODN106 and ODN108 groups were slightly lower than the antigen control group; at 21 days, the titers of ODN101, ODN103 and ODN105 groups increased by about 2, the ODN102 and ODN107 groups increased slightly, the ODN108 group was basically the same, and the ODN104 and ODN106 groups were lower than the antigen control group. Control group; according to the results on day 28, the titers of ODN101 and ODN103 were higher than 3, the titers of ODN105 were higher than 2, the titers of ODN102 and ODN107 were higher than 1, and the titers of ODN104, ODN106 and ODN108 were basically the same; according to the results on day 35, the titers of ODN101, ODN103, ODN105 and ODN107 were higher than 2, the titer of ODN102 was higher than 1, the titer of ODN104 and ODN106 were basically the same, and the titer of ODN108 was lower than the antigen control group.

[0141] In general, ODN101, ODN103 and ODN105 groups performed well on H9 and ND, respectively. In addition, ODN102, ODN107 and ODN108 groups were also able to improve antibody levels. ODN104 and ODN106 groups did not act as adjuvants.

[0142] (2) pcDNA 3.1-CpG

[0143] Peripheral blood was collected from 20 broilers randomly selected from each group of immunized white-feathered broilers at 14, 21, 28 and 35 days after immunization. Peripheral blood was collected from 20 broilers randomly selected from each group before immunization. Serum was separated and antibody levels were tested. The results show that ( Fig.16), the blank control serum antibody gradually decreased to almost zero on the 28th and 35th days, indicating that the chickens were not infected with wild viruses and the experiment was established. For H9 antibodies, compared with the antigen control, the antibody level was relatively low on the 14th day, among which pcDNA 3.1-CpG2 was lower than the antigen control group; from the 21st day results, pcDNA 3.1-CpG1 was 2 titers higher than the antigen control group, and pcDNA3.1-CpG2 was 0.5 titers higher than the antigen control group; from the 28th day results, pcDNA 3.1-CpG1 was more than 3 titers higher than the antigen control group, and pcDNA 3.1-CpG2 was 2 titers higher than the antigen control group; from the 35th day results, pcDNA 3.1-CpG1 was more than 3 titers higher than the antigen control group, and pcDNA 3.1-CpG2 was 2 titers higher than the antigen control group.

[0144] Peripheral blood was collected from 20 broilers randomly selected from each group of immunized white-feathered broilers at 14, 21, 28 and 35 days after immunization. Peripheral blood was collected from 20 broilers randomly selected from each group before immunization. Serum was separated and antibody levels were tested. The results show that ( Fig.17 ), the blank control serum antibody gradually decreased and was almost zero on the 28th and 35th days, indicating that the chickens were not infected with wild toxins and the experiment was established. For ND antibodies, compared with the antigen control, the antibody levels were relatively low on the 14th day, among which pcDNA 3.1-CpG1 was more than one titer higher than the antigen control group, and pcDNA 3.1-CpG2 was basically the same as the antigen control group; from the 21st day results, pcDNA 3.1-CpG1 was more than one titer higher than the antigen control group, and pcDNA 3.1-CpG2 was basically the same as the antigen control group; from the 28th day results, pcDNA 3.1-CpG1 was more than two titers higher than the antigen control group, and pcDNA 3.1-CpG2 was one titer higher than the antigen control group; from the 35th day results, pcDNA 3.1-CpG1 was more than three titers higher than the antigen control group, and pcDNA 3.1-CpG2 was one titer higher than the antigen control group.

[0145] From the overall results, pcDNA 3.1-CpG1 has no effect on H9 and ND, pcDNA 3.1-CpG2 is slightly worse than pcDNA 3.1-CpG1 but also has the effect of improving antibodies.

[0146] 4 Conclusion

[0147] At least three groups of CpG-ODN effective immune adjuvants were determined through experimental analysis, among which ODN101, ODN103 and ODN105 were the best. For the biosynthetic CpG combined double-stranded sequence, pcDNA 3.1-CpG1 was the best. The present invention provides new suggestions for improving the effect of the new flu two-combination vaccine.

[0148] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A CpG adjuvant, It is characterized in that The CpG adjuvant is any of the following: (1) any one of the CpG ODNs whose sequences are shown in SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5; (2) A plasmid containing the sequence shown in SEQ ID NO.

9.

2. The CpG adjuvant according to claim 1, It is characterized in that The plasmid in (2) is pcDNA 3.1(+) plasmid.

3. The CpG adjuvant according to claim 2, It is characterized in that The cloning site of the sequence shown in SEQ ID NO.9 in (2) in the pcDNA 3.1(+) plasmid is NheI.

4. A chicken vaccine composition, It is characterized in that The chicken vaccine composition contains an effective amount of the CpG adjuvant according to any one of claims 1 to 3.

5. The chicken vaccine composition according to claim 4, It is characterized in that The vaccine in the chicken vaccine composition is a combined inactivated vaccine of Newcastle disease and avian influenza H9 subtype.

6. The chicken vaccine composition according to claim 5, It is characterized in that The chicken vaccine composition has a CpG adjuvant concentration of 0.5-4 μg / 0.3 ml calculated on a total volume basis.

7. The chicken vaccine composition according to claim 6, It is characterized in that The chicken vaccine composition has a CpG adjuvant concentration of 1 μg / 0.3 ml calculated on a total volume basis.

8. The chicken vaccine composition according to claim 7, It is characterized in that The chicken vaccine composition has a CpG adjuvant concentration of 3 μg / 0.3 ml calculated on a total volume basis.

9. Use of the CpG adjuvant according to any one of claims 1 to 3 in preparing a chicken vaccine composition.

10. The use according to claim 9, It is characterized in that The vaccine in the chicken vaccine composition is a combined inactivated vaccine of Newcastle disease and avian influenza H9 subtype.